Helsinn Group’s representative office in China: Official inauguration

4 December 2013

Helsinn and Chugai Pharma Marketing enter into agreement for rights of Anamorelin, currently in development for treatment of anorexia-cachexia syndrome related to non-small cell lung cancer in top EU markets

12 November 2013

10 young students from the Sopraceneri area receive Helsinn Advanced Synthesis SA 2013/2014 educational scholarships

9 October 2013

Helsinn to launch sales organization in the United States

4 October 2013

Very positive Clinical Phase I/IIa results for Calcipotriol AKVANO formulation for the treatment of Psoriasis

13 September 2013

Helsinn Group and Eisai Inc. Announce Top-Line Results for Pivotal Studies of the Investigational Fixed-Dose Combination of Netupitant and Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting

16 May 2013

NEWSOur new plant for CHO based mAb or Recombinant Protein manufacturing is ready for the qualification phase

19 February 2013